Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Brooke

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Cell Reports|January 16, 2025
Probing the functional constraints of influenza A virus NEP by deep mutational scanningQi Wen Teo, Yiquan Wang, Huibin Lv, et al.
Immunity|November 15, 2023
Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidaseRuipeng Lei, Wooseob Kim, Huibin Lv, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2020
Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 <i>in vitro</i>Nir Drayman, Krysten A Jones, Saara-Anne Azizi, et al.
The Journal of Infectious Diseases|June 30, 2021
Longitudinal Assessment of Diagnostic Test Performance Over the Course of Acute SARS-CoV-2 InfectionRebecca L Smith, Laura L Gibson, Pamela P Martinez, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2021
Longitudinal assessment of diagnostic test performance over the course of acute SARS-CoV-2 infectionRebecca L Smith, Laura L Gibson, Pamela P Martinez, et al.
Medrxiv : the Preprint Server for Health Sciences|July 20, 2021
Daily sampling of early SARS-CoV-2 infection reveals substantial heterogeneity in infectiousnessRuian Ke, Pamela P Martinez, Rebecca L Smith, et al.
Nature Microbiology|April 28, 2022
Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousnessRuian Ke, Pamela P Martinez, Rebecca L Smith, et al.
Science (New York, N.Y.)|July 21, 2021
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2Nir Drayman, Jennifer K DeMarco, Krysten A Jones, et al.
Open Forum Infectious Diseases|July 6, 2022
Longitudinal Analysis of SARS-CoV-2 Vaccine Breakthrough Infections Reveals Limited Infectious Virus Shedding and Restricted Tissue DistributionRuian Ke, Pamela P Martinez, Rebecca L Smith, et al.
Medrxiv : the Preprint Server for Health Sciences|September 8, 2021
Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted tissue distributionRuian Ke, Pamela P Martinez, Rebecca L Smith, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Cell Reports|January 16, 2025
Probing the functional constraints of influenza A virus NEP by deep mutational scanningQi Wen Teo, Yiquan Wang, Huibin Lv, et al.
Immunity|November 15, 2023
Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidaseRuipeng Lei, Wooseob Kim, Huibin Lv, et al.
Biorxiv : the Preprint Server for Biology|September 10, 2020
Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 <i>in vitro</i>Nir Drayman, Krysten A Jones, Saara-Anne Azizi, et al.
The Journal of Infectious Diseases|June 30, 2021
Longitudinal Assessment of Diagnostic Test Performance Over the Course of Acute SARS-CoV-2 InfectionRebecca L Smith, Laura L Gibson, Pamela P Martinez, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2021
Longitudinal assessment of diagnostic test performance over the course of acute SARS-CoV-2 infectionRebecca L Smith, Laura L Gibson, Pamela P Martinez, et al.
Medrxiv : the Preprint Server for Health Sciences|July 20, 2021
Daily sampling of early SARS-CoV-2 infection reveals substantial heterogeneity in infectiousnessRuian Ke, Pamela P Martinez, Rebecca L Smith, et al.
Nature Microbiology|April 28, 2022
Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in infectiousnessRuian Ke, Pamela P Martinez, Rebecca L Smith, et al.
Science (New York, N.Y.)|July 21, 2021
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2Nir Drayman, Jennifer K DeMarco, Krysten A Jones, et al.
Open Forum Infectious Diseases|July 6, 2022
Longitudinal Analysis of SARS-CoV-2 Vaccine Breakthrough Infections Reveals Limited Infectious Virus Shedding and Restricted Tissue DistributionRuian Ke, Pamela P Martinez, Rebecca L Smith, et al.
Medrxiv : the Preprint Server for Health Sciences|September 8, 2021
Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted tissue distributionRuian Ke, Pamela P Martinez, Rebecca L Smith, et al.
Pageof 8